Shouyao Holdings' Fourth-Generation ALK Inhibitor SY-12321 Capsule Receives NMPA Clinical Trial Approval

SHOUYAO HOLDINGS, a Beijing-based biopharmaceutical company listed on Shanghai's STAR Market under ticker 688197, has cleared a key regulatory hurdle in its push to develop next-generation cancer therapies.

On July 16, the company said it received a Clinical Trial Approval Notice from China's National Medical Products Administration for SY-12321 capsules — a drug candidate designed to tackle one of oncology's most stubborn problems: drug resistance.

The approval covers monotherapy use in anaplastic lymphoma kinase (ALK)-positive advanced solid tumors. ALK-positive cancers have become increasingly tractable thanks to a succession of targeted inhibitors. But resistance inevitably emerges, and SHOUYAO is betting its latest candidate can address what earlier drugs cannot.

A Fourth-Generation Bet

SY-12321 is a Category 1 innovative drug — China's designation for novel chemical entities — and a fourth-generation small-molecule ALK inhibitor. It was developed entirely in-house by SHOUYAO, according to the company's announcement.

The drug is positioned to target resistance that arises after treatment with third-generation ALK inhibitors, with a particular focus on resistance driven by ALK compound mutations. That is a narrow but clinically significant niche: patients who progress on third-generation therapy have limited options, and the unmet need is acute.

No Domestic Rivals — Yet

As of the announcement date, no fourth-generation ALK inhibitor has been approved for market in China, the company said, citing publicly available information. Moreover, SHOUYAO's SY-12321 is the only fourth-generation ALK inhibitor that has received approval to enter clinical research in the country.

That first-mover advantage, however, comes with caveats. The drug is still in early-stage clinical testing, and the path from Phase I to approval is long and uncertain.

Financial Backdrop

SHOUYAO is a pre-profit biotech firm. In the first quarter of 2026, the company reported revenue of RMB 28 million and a net loss attributable to parent company shareholders of RMB 15.09 million, according to its public filings.

The clinical trial approval marks a milestone for the company's pipeline, but it also underscores the capital-intensive nature of drug development — and the distance between a regulatory green light and commercial revenue.